Pfizer CEO Looks for More Deals as Drugmaker Mulls Split

  • Managers still targeting decision about split by end of 2016
  • CEO seeking experimental drugs that are close to hit market

Can Pfizer's Big Beat Lead to an Innovative Spilt?

Pfizer Inc. is interested in buying drugmakers with products that are close to hitting the market, while considering a split of the business in the wake of failed takeover attempts of Allergan Plc and AstraZenca Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.